GU Cancers 2023 | cfDNA for MRD detection in non-muscle invasive bladder cancer

Kyle M. Rose, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses a prospective study was carried out to assess utDNA’s ability to measure minimal residual disease (MRD) at the time of standard-of-care repeat transurethral resection of bladder tumor (rTURBT) in non-muscle invasive bladder cancer (NMIBC). The primary endpoint was the detection of utDNA to predict MRD at the time of repeat-TURBT. Eleven patients underwent rTURBT for high-risk NMIBC and residual tumor was detected at rTURBT in 73% of patients. Conclusively, urinary tumor DNA showed promise as a surrogate for MRD, holding the potential to predict TURBT pathology for NMIBC. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.